Affinage

ALAS1

5-aminolevulinate synthase, non-specific, mitochondrial · UniProt P13196

Length
640 aa
Mass
70.6 kDa
Annotated
2026-06-09
38 papers in source corpus 15 papers cited in narrative 15 extracted findings
Cross-family judge vs UniProt: tie faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ALAS1 is the rate-limiting mitochondrial enzyme of heme biosynthesis whose output (5-aminolevulinic acid) supports cellular heme-dependent processes ranging from iron utilization to myeloid maturation (PMID:36318618, PMID:29954941). Its level is set by tightly coupled transcriptional and post-translational feedback: heme destabilizes ALAS1 by driving heme-dependent assembly of the mature mitochondrial protein with the ATP-dependent matrix protease CLPXP through an N-terminal heme-binding motif, with oxidative modification additionally recruiting LONP1 (PMID:27496948), and POLDIP2 acting as the heme-sensing adaptor that recognizes heme-bound ALAS1 and delivers it to CLPXP for degradation [PMID:bio_10.1101_2024.07.05.602318]. Heme also lowers ALAS1 mRNA stability while paradoxically stabilizing the cytosolic precursor protein (PMID:18719978). Transcription is induced by ligand-activated nuclear receptors acting through DR4/DR5 drug-responsive enhancers (PMID:12121995) and by PPARα/RXR/PGC-1α at upstream PPAR binding sites during fasting (PMID:19289130), and is repressed by the circadian factor REV-ERBα (PMID:26102301). Beyond its canonical mitochondrial role, ALAS1 has a heme-independent cytoplasmic function as a repressor of miRNA accumulation that limits Argonaute complex assembly, a property unique among heme-biosynthesis enzymes (PMID:39700288). Functionally, ALAS1 abundance governs mitochondrial iron handling, where its loss causes mitochondrial iron overload, lipid peroxidation, and ferroptosis rescuable by 5-ALA (PMID:36318618), and ALAS1-dependent heme is required for neutrophil maturation and bactericidal function (PMID:29954941). Its proper mitochondrial localization is also a target of viral antagonism, as measles virus V protein sequesters ALAS1 in the cytosol to trigger mtDNA-driven innate immune signaling (PMID:36802406).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 1995 Medium

    Establishing the chromosomal location of the housekeeping ALAS1 gene provided the genomic anchor for subsequent regulatory and disease studies.

    Evidence PCR mapping of somatic cell and radiation hybrids

    PMID:7698013

    Open questions at the time
    • No functional or regulatory information from mapping alone
    • Does not address gene structure or promoter organization
  2. 2001 Medium

    It was unknown how a single housekeeping gene achieves tissue-specific expression; transcript mapping showed liver and brain use distinct initiation sites directed by similar core promoters, with the liver TATA box dedicated to drug induction.

    Evidence Transcript mapping in human/rat tissues and TATA box mutagenesis in HeLa cells

    PMID:11267664

    Open questions at the time
    • Trans-acting factors driving tissue-specific start site choice not identified
    • Functional consequence of brain-specific initiation not defined
  3. 2002 High

    The molecular basis of drug-mediated ALAS1 induction was resolved by showing a xenobiotic-sensing nuclear receptor binds two DR4/DR5 enhancer elements to transactivate the gene.

    Evidence Reporter assays, enhancer mutagenesis, and EMSA in LMH hepatoma cells (chicken CXR)

    PMID:12121995

    Open questions at the time
    • Demonstrated with chicken CXR; human receptor identity at these sites not established here
    • Does not address protein-level regulation
  4. 2009 High

    Linking ALAS1 to metabolic state, PPARα was shown to directly drive ALAS1 transcription during fasting via two upstream PPAR binding sites, explaining nutritional induction of heme synthesis.

    Evidence Reporter assays, PPARα siRNA, and ChIP for PPARα/RXR/PGC-1α/Pol II in human hepatocytes and HepG2

    PMID:19289130

    Open questions at the time
    • Interplay with drug-responsive and circadian inputs not integrated
    • Tissue scope beyond liver not addressed
  5. 2009 Low

    A candidate hormonal regulatory input was probed by showing ERα can activate ALAS1 through a half-palindromic estrogen response element.

    Evidence Co-transfection reporter assay with ERα and ERE mutagenesis in HepG2 cells

    PMID:19656447

    Open questions at the time
    • Reporter assay only, no endogenous ChIP or knockdown validation
    • Physiological relevance of the -853 variant not established
  6. 2008 Medium

    How heme negatively feeds back on ALAS1 began to be parsed by showing heme/CoPP shortens ALAS1 mRNA half-life while stabilizing the cytosolic precursor and reducing mature mitochondrial protein.

    Evidence Actinomycin D mRNA stability and cycloheximide protein stability assays in human hepatocytes

    PMID:18719978

    Open questions at the time
    • Protease and adaptor machinery not yet identified
    • Mechanism distinguishing precursor stabilization from mature degradation unresolved
  7. 2016 High

    The post-translational arm of heme feedback was defined mechanistically: mature ALAS1 forms a heme-dependent complex with the CLPXP protease through an N-terminal heme-binding motif, with LONP1 recruited upon oxidative modification.

    Evidence Co-IP, CLPX/CLPP siRNA, and heme-motif mutagenesis in HepG2 cells

    PMID:27496948

    Open questions at the time
    • How heme-bound ALAS1 is selected and presented to CLPXP not resolved
    • Relative contributions of CLPXP versus LONP1 not quantified
  8. 2024 High

    The missing heme-sensing component of degradation was identified: POLDIP2 directly recognizes heme-bound ALAS1 and acts as the adaptor delivering it to CLPXP, while the ALAS1 C-terminal element is dispensable for binding but required for degradation.

    Evidence Biochemical reconstitution, POLDIP2 depletion turnover assays, and direct binding assays (preprint)

    PMID:bio_10.1101_2024.07.05.602318

    Open questions at the time
    • Preprint, not peer-reviewed at time of capture
    • Structural basis of POLDIP2 heme-ALAS1 recognition not defined
  9. 2015 Medium

    A circadian repressive input was established by showing REV-ERBα represses ALAS1 transcription, connecting heme synthesis to the clock.

    Evidence REV-ERBα siRNA and agonist/antagonist treatment in rat granulosa cells

    PMID:26102301

    Open questions at the time
    • Direct promoter occupancy not demonstrated
    • Demonstrated in granulosa cells; relevance to hepatic rhythm not shown
  10. 2018 Medium

    The physiological consequence of ALAS1-derived heme in immune cells was shown: Alas1 deficiency blocks neutrophil maturation and impairs bactericidal function due to loss of heme-dependent granule activities.

    Evidence Alas1-deficient zebrafish, maturation staging, granule assays, and E. coli challenge

    PMID:29954941

    Open questions at the time
    • Conservation of the maturation block in mammalian neutrophils not confirmed
    • Specific heme-dependent granule effectors not enumerated
  11. 2021 Medium

    Gene-dosage effects on fasting induction were examined, showing heterozygous Alas1-null mice manifest induced ALAS1 protein and reduced hepatic HMOX1 without compensatory upregulation of the wild-type allele.

    Evidence Heterozygous Alas1-null mouse (βGEO), fasting induction, RT-PCR and Western blotting

    PMID:34900592

    Open questions at the time
    • Mechanism of allele-specific protein manifestation not resolved
    • Link between ALAS1 dosage and HMOX1 not mechanistically explained
  12. 2022 High

    ALAS1 was placed in a ferroptosis pathway by showing doxorubicin lowers ALAS1, causing mitochondrial iron overload and ferroptosis in cardiomyocytes that is rescued by ALAS1 overexpression or 5-ALA.

    Evidence ALAS1 overexpression rescue and 5-ALA supplementation in cardiomyocytes and mice

    PMID:36318618

    Open questions at the time
    • Mechanism linking heme synthesis to iron utilization and lipid peroxidation not fully defined
    • Generality beyond cardiomyocytes not established
  13. 2023 High

    ALAS1 mitochondrial localization was shown to be a viral target: measles V protein sequesters ALAS1 in the cytosol, reducing mitochondrial integrity and triggering mtDNA-driven RIG-I/type I interferon signaling.

    Evidence Subcellular fractionation with V-deficient virus control and IFNAR-/- hCD46 mouse infection

    PMID:36802406

    Open questions at the time
    • Direct V-protein/ALAS1 binding interface not mapped
    • Whether ALAS1 catalytic loss versus mislocalization drives the phenotype not separated
  14. 2024 High

    A noncanonical function was uncovered: cytoplasmic ALAS1 acts heme-independently to repress miRNA accumulation by limiting Argonaute complex assembly, a property unique among heme-biosynthesis enzymes.

    Evidence Conditional Alas1 depletion in mouse hepatocytes, Argonaute assembly and miRNA assays

    PMID:39700288

    Open questions at the time
    • Molecular interface between ALAS1 and Argonaute not defined
    • How cytoplasmic versus mitochondrial pools are partitioned not resolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the multiple regulatory inputs (drug, metabolic, circadian, heme feedback) and the mitochondrial versus cytoplasmic functional pools are integrated to set ALAS1 activity in vivo remains unresolved.
  • No unified model coordinating transcriptional and degradative regulation
  • Structural basis of heme sensing across CLPXP/POLDIP2/LONP1 unresolved
  • Mechanism of the cytoplasmic Argonaute-repressing function unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 1 GO:0098772 molecular function regulator activity 1
Localization
GO:0005739 mitochondrion 3 GO:0005829 cytosol 3
Pathway
GO:0140096 catalytic activity, acting on a protein 2

Evidence

Reading pass · 15 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2016 ALAS1 undergoes heme-dependent degradation in mitochondria via the ATP-dependent protease ClpXP (CLPX/CLPP heteromultimer). ALAS1 forms a complex with ClpXP in a heme-dependent manner, and siRNA-mediated suppression of CLPX or CLPP induces ALAS1 accumulation. A specific heme-binding motif at the N-terminal end of the mature ALAS1 protein is required for this heme-dependent complex formation. Additionally, hemin-mediated oxidative modification of ALAS1 recruits LONP1, another mitochondrial matrix protease, into the ALAS1 complex. Co-immunoprecipitation, siRNA knockdown of CLPX/CLPP in HepG2 cells, site-directed mutagenesis of heme-binding motif The Journal of biological chemistry High 27496948
2024 POLDIP2 serves as a heme-sensing adaptor protein that delivers ALAS1 to the mitochondrial protease CLPXP for degradation, establishing the molecular basis of heme-induced negative feedback. POLDIP2 directly recognizes heme-bound ALAS1 to drive assembly of the degradation complex. The C-terminal element of ALAS1 is dispensable for interaction with POLDIP2 but necessary for degradation by CLPXP. Biochemical reconstitution, loss-of-function (POLDIP2 depletion) with ALAS turnover assay, direct binding assays bioRxivpreprint High bio_10.1101_2024.07.05.602318
2008 Heme and cobalt protoporphyrin (CoPP) downregulate ALAS1 mRNA by decreasing mRNA half-life (post-transcriptional mechanism), while simultaneously upregulating cytosolic precursor ALAS1 protein by increasing its half-life. Mature mitochondrial ALAS1 protein is downregulated 60–70% by heme/CoPP treatment. Actinomycin D mRNA stability assay, cycloheximide protein stability assay, Western blotting in human hepatocytes Molecular and cellular biochemistry Medium 18719978
2002 Drug-induced transcriptional activation of ALAS1 is mediated by the chicken xenobiotic-sensing nuclear receptor (CXR) binding to two drug-responsive enhancer sequences (DR5 and DR4 type nuclear receptor binding sites) in the 5'-flanking region of the gene. Mutagenesis of individual nuclear receptor binding sites reduced enhancer activation by ≥60%, and mutagenesis of both sites virtually eliminated it. EMSA confirmed direct CXR binding to these sites. Reporter gene assays in hepatoma cell line LMH, site-directed mutagenesis of nuclear receptor binding sites, electrophoretic mobility shift assay (EMSA), transactivation studies The Journal of biological chemistry High 12121995
2009 PPARα directly regulates ALAS1 transcription in human liver via two functional PPAR binding sites at positions -9 kb and -2.3 kb relative to the ALAS1 transcription start site. PPARα agonists induced ALAS1 mRNA in primary human hepatocytes and HepG2 cells; effect was abolished by PPARα silencing. ChIP showed increased association of PPARα, RXR, PGC-1α, and activated RNA Pol II with the ALAS1 transcription start site upon PPARα ligand treatment and during fasting. Reporter gene assays, PPARα siRNA knockdown, chromatin immunoprecipitation (ChIP), primary human hepatocyte treatment Journal of molecular biology High 19289130
2001 Human ALAS1 gene transcription uses tissue-specific initiation sites directed by closely similar core promoters. In liver, initiation is TATA-driven from a single downstream site used exclusively for drug induction. In brain, initiation occurs from within and upstream of the TATA box including an initiator-like element. Mutation of the TATA box in transfected HeLa cells activates upstream start sites, recapitulating the brain pattern. Transcript mapping in human and rat tissues, TATA box mutagenesis in transfected HeLa cells, mRNA transcript analysis Biochimica et biophysica acta Medium 11267664
2000 The beta subunit of ATP-specific succinyl-CoA synthetase (SCS-betaA) specifically associates with the erythroid-specific ALAS isoform (ALAS-E) but NOT with the nonspecific ALAS (ALAS-N/ALAS1) in mitochondria. The ALAS-E mutant D190V (found in pyridoxine-refractory X-linked sideroblastic anemia) failed to associate with SCS-betaA, suggesting the interaction promotes efficient succinyl-CoA use or mitochondrial translocation of ALAS-E. Yeast two-hybrid screen of human bone marrow cDNA library, transient expression and co-immunoprecipitation The Journal of clinical investigation Medium 10727444
2022 Doxorubicin intercalates into mitochondrial DNA and decreases the abundance of ALAS1 (the rate-limiting enzyme in heme synthesis), thereby impairing iron utilization, causing mitochondrial iron overload and ferroptosis in cardiomyocytes. ALAS1 overexpression prevented this iron overload outcome. Supplementation with 5-ALA (the product of ALAS1) suppressed iron overload and lipid peroxidation in both cultured cardiomyocytes and mice. ALAS1 overexpression rescue experiment in cardiomyocytes, 5-ALA supplementation in cardiomyocytes and mouse model, measurement of mitochondrial iron and lipid peroxidation Science signaling High 36318618
2024 ALAS1 functions as a general repressor of miRNA accumulation and limits Argonaute complex assembly and activity in a heme-independent manner via a cytoplasmic role (previously considered inactive outside mitochondria). Conditional depletion of ALAS1 activity from mouse hepatocytes increases miRNA levels and enhances siRNA-mediated knockdown. This noncanonical function is specific to ALAS1 and not shared by other heme biosynthesis enzymes. Conditional ALAS1 depletion in mouse hepatocytes, Argonaute complex assembly assays, miRNA quantification, siRNA knockdown efficiency assays Science (New York, N.Y.) High 39700288
2023 Measles virus V protein antagonizes ALAS1 by sequestering it to the cytosol, preventing its normal mitochondrial localization. This relocalization decreases mitochondrial volume and impairs mitochondrial metabolic potential, leading to release of mitochondrial dsDNA into the cytosol. Released mtDNA is transcribed by DNA-dependent RNA Pol III to produce dsRNA intermediates that activate RIG-I and type I interferon production. Subcellular fractionation post-infection, MeV mutant lacking V gene as control, IFNAR-/- hCD46 transgenic mouse infection model, deep sequencing of cytosolic mtDNA PLoS pathogens High 36802406
2015 REV-ERBα represses ALAS1 transcription in rat granulosa cells. REV-ERBα knockdown via siRNA upregulated ALAS1 transcript levels, and treatment with REV-ERBα agonists (GSK4112, heme) repressed ALAS1 expression, while antagonist SR8278 increased it. Rev-erbα siRNA knockdown, agonist/antagonist treatment, real-time monitoring of Per2-dLuc circadian oscillations in primary granulosa cells Chronobiology international Medium 26102301
2009 Estrogen receptor alpha (ERα) mediates increased transcriptional activity of ALAS1 through a half-palindromic estrogen response element in the 5' regulatory region (near position -853). Co-transfection with ERα expression vector in HepG2 cells showed the -853C>T variant generates a stronger enhancer response (66% increase) in the presence of estrogen compared to wild-type (47% increase). Co-transfection reporter assay in HepG2 cells with ERα expression vector, site-directed mutagenesis of putative estrogen response element Cellular and molecular biology Low 19656447
2021 In heterozygous ALAS1 null mice, fasting induces ALAS1 mRNA in both WT and heterozygous mice, but only heterozygous mice show this manifest as increased ALAS1 protein. Hepatic heme oxygenase 1 (HMOX1) mRNA expression was significantly lower in heterozygous mice. No upregulation of the WT allele ALAS1 mRNA was detected as a compensatory mechanism in heterozygous liver. Heterozygous ALAS1 null mouse model (βGEO insert), fasting induction experiment, RT-PCR, Western blotting, HMOX1 mRNA measurement Molecular genetics and metabolism reports Medium 34900592
2018 In zebrafish, Alas1 deficiency blocks neutrophil maturation at a specific stage (proper initiation preserved but further maturation blocked) due to heme deficiency, resulting in lipid storage and granule formation deficiencies, and loss of heme-dependent granule protein activities. Alas1-deficient zebrafish showed impaired bactericidal ability and augmented inflammatory responses when challenged with E. coli. Alas1-deficient zebrafish model, neutrophil maturation staging, granule protein activity assays, bacterial challenge Haematologica Medium 29954941
1995 The human housekeeping ALAS1 gene was mapped to chromosome band 3p21.1 by PCR analysis of somatic cell and radiation hybrids. PCR analysis of somatic cell hybrids and radiation hybrids Cytogenetics and cell genetics Medium 7698013

Source papers

Stage 0 corpus · 38 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2015 Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification. Molecular therapy. Nucleic acids 113 26528940
2022 Doxorubicin causes ferroptosis and cardiotoxicity by intercalating into mitochondrial DNA and disrupting Alas1-dependent heme synthesis. Science signaling 112 36318618
2014 RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice. Proceedings of the National Academy of Sciences of the United States of America 103 24821812
2016 Novel Mechanisms for Heme-dependent Degradation of ALAS1 Protein as a Component of Negative Feedback Regulation of Heme Biosynthesis. The Journal of biological chemistry 92 27496948
2000 Interaction between succinyl CoA synthetase and the heme-biosynthetic enzyme ALAS-E is disrupted in sideroblastic anemia. The Journal of clinical investigation 77 10727444
2002 Drugs mediate the transcriptional activation of the 5-aminolevulinic acid synthase (ALAS1) gene via the chicken xenobiotic-sensing nuclear receptor (CXR). The Journal of biological chemistry 46 12121995
2019 Synergistic antitumor activity of artesunate and HDAC inhibitors through elevating heme synthesis via synergistic upregulation of ALAS1 expression. Acta pharmaceutica Sinica. B 33 31649844
2008 Differential regulation of human ALAS1 mRNA and protein levels by heme and cobalt protoporphyrin. Molecular and cellular biochemistry 33 18719978
2021 Renal Function Decline With Small Interfering RNA Silencing Aminolevulinic Acid Synthase 1 (ALAS1). Kidney international reports 31 34307985
1997 Alanyl-tRNA synthetase gene of the extreme acidophilic chemolithoautotrophic Thiobacillus ferrooxidans is highly homologous to alaS genes from all living kingdoms but cannot be transcribed from its promoter in Escherichia coli. Microbiology (Reading, England) 25 9245807
2017 Downregulation of ALAS1 by nicarbazin treatment underlies the reduced synthesis of protoporphyrin IX in shell gland of laying hens. Scientific reports 20 28740143
1995 Assignment of the human housekeeping delta-aminolevulinate synthase gene (ALAS1) to chromosome band 3p21.1 by PCR analysis of somatic cell hybrids. Cytogenetics and cell genetics 18 7698013
2001 Alternative splicing and tissue-specific transcription of human and rodent ubiquitous 5-aminolevulinate synthase (ALAS1) genes. Biochimica et biophysica acta 17 11267664
2024 Noncanonical role of ALAS1 as a heme-independent inhibitor of small RNA-mediated silencing. Science (New York, N.Y.) 15 39700288
2020 Heterozygous disruption of ALAS1 in mice causes an accelerated age-dependent reduction in free heme, but not total heme, in skeletal muscle and liver. Archives of biochemistry and biophysics 15 33307066
2018 Alas1 is essential for neutrophil maturation in zebrafish. Haematologica 15 29954941
2015 Integration of the nuclear receptor REV-ERBα linked with circadian oscillators in the expressions of Alas1, Ppargc1a, and Il6 genes in rat granulosa cells. Chronobiology international 15 26102301
2009 Peroxisome proliferator-activated receptor alpha controls hepatic heme biosynthesis through ALAS1. Journal of molecular biology 14 19289130
2020 Genome-wide identification, characterisation and expression analysis of the ALAS gene in the Yesso scallop (Patinopecten yessoensis) with different shell colours. Gene 10 32622991
1998 Reactions of H(3)Al.NMe(3) with E(SiMe(3))(3) (E = P, As). Structural Characterization of the Trimer [H(2)AlP(SiMe(3))(2)](3) and Base-Stabilized Adduct [H(2)AlAs(SiMe(3))(2)].NMe(3) and Their Thermal Decomposition toward Nanocrystalline AlP and AlAs, Respectively. Inorganic chemistry 9 11670444
1993 The role of ALA-S and ALA-D in regulating porphyrin biosynthesis in a normal and a HEM R+ mutant strain of Saccharomyces cerevisiae. Yeast (Chichester, England) 9 8465603
2023 Antagonism of ALAS1 by the Measles Virus V protein contributes to degradation of the mitochondrial network and promotes interferon response. PLoS pathogens 8 36802406
2020 Inhibition of ALAS1 activity exerts anti-tumour effects on colorectal cancer in vitro. Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association 8 32270771
2016 Short Communication: Molecular cloning and expression pattern of the porcine 5-aminolevulinate synthase 1 (ALAS1) gene and its association with reproductive traits. Genetics and molecular research : GMR 5 26910002
2015 Non-Conserved Residues in Clostridium acetobutylicum tRNA(Ala) Contribute to tRNA Tuning for Efficient Antitermination of the alaS T Box Riboswitch. Life (Basel, Switzerland) 5 26426057
2009 Functional analysis of the 5' regulatory region of the 5-aminolevulinate synthase (ALAS1) gene in response to estrogen. Cellular and molecular biology (Noisy-le-Grand, France) 3 19656447
2024 Association of DNA methylation, polymorphism and mRNA level of ALAS1 with antituberculosis drug-induced liver injury. Pharmacogenomics 2 39263813
2024 Association of Gene Polymorphisms and Serum Levels of ALAS1 with the Risk of Anti-Tuberculosis Drug-Induced Liver Injury. Journal of clinical pharmacology 2 39297668
2021 Complex response to physiological and drug-induced hepatic heme demand in monoallelic ALAS1 mice. Molecular genetics and metabolism reports 2 34900592
2025 Redox status regulates eggshell color by modulating protoporphyrin IX biosynthesis via the SIRT1/PGC-1α/ALAS1 axis in brown-shelled hens. Journal of animal science and biotechnology 1 41267070
2011 Improvement of performance of InAs quantum dot solar cell by inserting thin AlAs layers. Nanoscale research letters 1 21711628
2009 Lattice dynamics and Raman scattering by phonons of GaAs/AlAs(001) superlattices. Journal of physics. Condensed matter : an Institute of Physics journal 1 21828489
2007 [Purification and production of the extracellular 5-aminolevulinate from recombiniant Escherichia coli expressing yeast ALAS]. Sheng wu gong cheng xue bao = Chinese journal of biotechnology 1 17578005
2025 From Deficiency to Therapy: Systemic Consequences of ALAS1 Disruption and the Protective Role of 5-ALA. Life (Basel, Switzerland) 0 40868906
2025 Coherent phonon flatband generated in GaAs/AlAs superlattices via layer-selective optical pumping. Nature communications 0 41006224
2024 Influence of temperature on bandgap shifts, optical properties and photovoltaic parameters of GaAs/AlAs and GaAs/AlSbp-nheterojunctions: insights fromab-initioDFT + NEGF studies. Journal of physics. Condensed matter : an Institute of Physics journal 0 38330463
2023 ALAS1 associated with goat kidding number trait was regulated by the transcription factor ASCL2 to affect granulosa cell proliferation. Animal genetics 0 36632647
1998 Regulatory role of ALA-S and ALA-D in a haem-deficient mutant of Saccharomyces cerevisiae. Cellular and molecular biology (Noisy-le-Grand, France) 0 9678894

Missed literature

Know a paper Affinage missed for ALAS1? Flag it for the maintainers and the community.

No submissions yet.